Athenex

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athenex - China API Business engages in Active Pharmaceutical Ingredient (API) manufacturing operations.

BUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that it has entered into a definitive agreement for ImmunityBio, Inc. (NASDAQ: IBRX) to assume its leasehold interest in a manufacturing facility in Dunkirk, New York, and certain related assets for approximately $38 million, subject to adjustment at closing. Proceeds from the sale will be used to service the Company's debt obligations and for other general corporate purposes. The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2022.

Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility

SAN DIEGO, Calif. & BUFFALO, N.Y.--(BUSINESS WIRE)---- $ATNX #breastcancer--Athenex, Inc. (ATNX) Misstated the Efficacy of its Lead Drug Candidate and the Likelihood the FDA Would Approve its New Drug Application

SHAREHOLDER ALERT: Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareholders

The Company will host a virtual Key Opinion Leader event today at 9:00 a.m. ET to discuss its CAR-NKT cell therapy platform

Athenex to Host a KOL Webinar Today on CAR-NKT Cell Approach to Cancer and Latest Data at the 63rd ASH Annual Meeting

BUFFALO, N.Y., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its Marketing Authorization Application (MAA) for oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of advanced breast cancer has been validated by the United Kingdom's (UK) Medicines and Healthcare products Regulatory Agency (MHRA) for review . The application qualifies for a 150 day assessment by which a decision on approvability of the product will be provided.

Athenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex Inc's (NASDAQ: ATNX) abstract for subgroup analysis of its Phase 3 study of oral paclitaxel and encequidar (Oral Paclitaxel) for metastatic breast cancer has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium. The abstract and poster provide data from a post hoc, subgroup analysis of safety, progression-free survival, and overall survival of patients with elevated liver enzymes.

Athenex To Present Subgroup Analysis Of Oral Paclitaxel-Encequidar Combo Data From Breast Cancer Trial

Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock?

BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, Senior Director, Corporate Development will present at the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 3:55 pm ET.

Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference

Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs to target solid tumors Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs to target solid tumors

Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies

Athenex, Inc. (ATNX) CEO Johnson Lau on Q3 2021 Results - Earnings Call Transcript

Results from five patients showed best responses of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response (CR).

Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition

Athenex (ATNX) has been struggling lately, but the selling pressure may be coming to an end soon.

Athenex (ATNX) Sees Hammer Chart Pattern: Time to Buy?

BUFFALO, N.Y., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2021, on Thursday, November 4, 2021. Athenex's management team will host a conference call and live audio webcast at 10:00 a.m. Eastern Time.

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021

BUFFALO, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2021, on Friday, November 5, 2021, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00am Eastern Time.

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021

Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR)

Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Cell Therapy

Athenex (ATNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging 25.6% in 4 Weeks, Here's Why the Trend Might Reverse for Athenex (ATNX)

BUFFALO, N.Y., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently held a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for oral paclitaxel and encequidar (Oral Paclitaxel) in metastatic breast cancer (mBC). The purpose of the meeting was to review with the FDA a proposed design for a new clinical trial intended to address the deficiencies raised in the Complete Response Letter received in February 2021 and discuss the potential regulatory path forward for Oral Paclitaxel in mBC in the U.S.

Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer

Hall of Fame Resort & Entertainment

NGL Energy Partners

9 Meters Biopharma

Tuesday Morning Corp

Insiders are buying shares of these penny stocks this months; are you? The post 5 Penny Stocks To Buy According To Insiders In September appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Insiders In September

Athenex Inc (NASDAQ: ATNX) announced data presentation from a Phase 1 study evaluating encequidar (Oral Paclitaxel) in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in advanced solid malignancies. Paclitaxel is one of the most commonly used chemotherapies.

Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial

Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging anti-tumor activity (4 PR out of 8 evaluable patients) in NSCLC patients who failed prior PD1/PDL1 therapies Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging anti-tumor activity (4 PR out of 8 evaluable patients) in NSCLC patients who failed prior PD1/PDL1 therapies

Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021

BUFFALO, N.Y., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, Senior Director, Corporate Development will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Wednesday, September 22, 2021 at 10:45 a.m. ET.

Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & Med Tech Summit

Athenex, Inc. is a biopharmaceutical company developing and commercializing next-generation drugs for treating various cancers. Athenex's pipeline consists of four therapeutic programs, Orascovery (P-glycoprotein pump inhibitor), Src Kinase Inhibition, Cell Therapy, and Arginine Deprivation Therapy.

Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.

Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2021 Results - Earnings Call Transcript

Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and -0.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Reports Q2 Loss, Misses Revenue Estimates

Updated investors on FDA Type A Meeting for oral paclitaxel

Athenex Provides Second Quarter 2021 Corporate and Financial Update

Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada

News for Athenex Stock (ATNX)